| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. | Director | Common Stock | 2,198,457 | $3,847,299 | $1.75 | 29 Sep 2025 | Indirect |
| SAB Biotherapeutics, Inc. | Director | Series B Convertible Preferred Stock | 211,100 | 29 Sep 2025 | Indirect | ||
| SAB Biotherapeutics, Inc. | Director | Warrants (right to buy) | 114,250 | 22 Jul 2025 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | 29 Sep 2025 | 2 | +$3,045,000 | 4 | Director | 01 Oct 2025, 16:35 |
| SABS | SAB Biotherapeutics, Inc. | 22 Jul 2025 | 3 | $0 | 4 | Director | 24 Jul 2025, 16:30 |
| SABS | SAB Biotherapeutics, Inc. | 24 Nov 2023 | 3 | -$2,889,000 | 4 | Director | 28 Nov 2023, 16:05 |
| SABS | SAB Biotherapeutics, Inc. | 10 Nov 2023 | 1 | +$13,269,000 | 4/A | Director | 15 Nov 2023, 21:10 |
| SABS | SAB Biotherapeutics, Inc. | 23 Oct 2023 | 2 | +$16,269,000 | 4 | Director | 24 Oct 2023, 17:30 |
| SABS | SAB Biotherapeutics, Inc. | 02 Oct 2023 | 0 | $0 | 3 | Director | 10 Oct 2023, 16:05 |